BCL9 and neoplasm: The development of BCL9/9L inhibitors may provide an avenue for downstream β-catenin inhibition in these tumour subtypes.33 Several other small molecules have also come to light in recent years, including BBI608 (a STAT3 inhibitor) and CBP/ β-catenin antagonist, etc.34–36